Objectives of Present Proposal: To capitalize on the progress achieved during the past award period in collaboration with Dr. Wilbur H. Sawyer, Professor of Pharmacology, College of Physicians and Surgeons of Columbia University, New York, in studies on the design, synthesis and testing for potential clinical applications of the following: 1) Potent and selective antagonists of the antidiuretic responses to (AVP) for use as a) pharmacological tools for studying the contribution of vasopressin to water retention in normal and pathophysiological states, and b) therapeutic agents for the treatment of hyponatremias. 2) Potent and selective antagonists of the vasopressor responses to vasopressin for use in studies on the roles of vasopressin in regulating blood pressure under normal and pathophysiological states. 3) Potent and selective antagonists of in vivo oxytocic and milk-ejecting responses to oxytocin for possible use in the prevention of premature deliveries and as pharmacological tools. The proposed studies will focus on maximizing, potency, selectivity and duration of action by chemical modifications of the best lead compounds developed to date. The peptides will be synthesized in the P.I.'s laboratory. The pharmacological testing will be carried out in Dr. Sawyer's laboratory. Additional Objectives are: 4) In collaboration with Serge Jard, to correlate the in vivo potencies of selected AVP agonists and antagonists with their in vitro properties in binding and adenylate cyclase activation assays and to thus gain additional insights into the topochemical facets of neurohypophyseal peptide agonists and antagonists involved in a) binding and/or b) activation of specific receptors in a variety of tissues and c) prolonging their duration of action. 5) To continue to provide other investigators with samples of synthetic peptides for their independent investigations. Peptides from the P.I.'s laboratory have been and continue to be very useful pharmacological probes of the physiological roles of AVP and oxytocin.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM025280-15
Application #
3272899
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1978-07-01
Project End
1988-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
15
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Toledo
Department
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Busnelli, Marta; Kleinau, Gunnar; Muttenthaler, Markus et al. (2016) Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure. J Med Chem 59:7152-66
Manning, M; Misicka, A; Olma, A et al. (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24:609-28
Busnelli, Marta; Saulière, Aude; Manning, Maurice et al. (2012) Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 287:3617-29
Corbani, Maithe; Trueba, Miguel; Stoev, Stoytcho et al. (2011) Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. J Med Chem 54:2864-77
Albizu, Laura; Cottet, Martin; Kralikova, Michaela et al. (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 6:587-94
Mouillac, B; Manning, M; Durroux, T (2008) Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev Med Chem 8:996-1005
Chini, Bice; Manning, Maurice; Guillon, Gilles (2008) Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an ""easy guide"" to receptor pharmacology. Prog Brain Res 170:513-7
Manning, Maurice; Stoev, Stoytcho; Chini, Bice et al. (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170:473-512
Manning, Maurice (2008) Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective. Biopolymers 90:203-12
Albizu, Laura; Teppaz, Geraldine; Seyer, Rene et al. (2007) Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem 50:4976-85

Showing the most recent 10 out of 67 publications